Glyceride Patents (Class 514/786)
-
Publication number: 20090318570Abstract: The invention relates to a silicone-free skin protection composition, in particular a composition to protect against cold, containing the components a.) at least one oil with a pour point in accordance with DIN ISO 30 16 of ??10° C., b.) at least one polyol c.) at least one emulsifier d.) optionally at least one wax, where the viscosity difference in the temperature interval from +4° C. to +50° C. of highest and lowest viscosity of the skin protection composition has a value in the range from 0 to ?20 000 mPas.Type: ApplicationFiled: November 9, 2007Publication date: December 24, 2009Applicant: Evonik Stockhausen GmbHInventors: Marcel Veeger, Petra Allef
-
Publication number: 20090253812Abstract: The present invention is directed to the delivery of a variety of topically active materials from a class of compounds called spider esters, which are the topic of U.S. Pat. No. 7,437,707 incorporated herein by reference. According to this first aspect of the present invention, active ingredients are delivered more efficaciously to, and, where desired, through the skin (i.e., localized subdermal penetration). By “delivered more efficaciously” is meant a cream, lotion, gel or serum that is contacted with the skin such that the active ingredient(s) are delivered in a manner that has (i) the same or similar therapeutic effect but at lower dosage of the active ingredient(s), and/or (ii) the same or similar desired therapeutic effect over a longer period of time, and/or (iii) a better or improved therapeutic effect in comparison to the same dose of active ingredient(s) in another delivery vehicle.Type: ApplicationFiled: June 9, 2009Publication date: October 8, 2009Inventors: Kevin A. O'Lenick, Anthony J. O'Lenick, JR.
-
Publication number: 20090192233Abstract: The invention proposes a cosmetic or pharmaceutical preparation containing a mixture of medium-chain, preferably saturated triglycerides with a fatty acid chain length of between C8 and C10 of between 60% and 98% and a content of saturated, long-chain, preferably saturated triglycerides with a fatty acid chain length of between C18 and C24 of between 2% and 40% as a vegetable replacement for VaselineType: ApplicationFiled: January 2, 2009Publication date: July 30, 2009Applicant: Walter Rau Neusser Ol und Fett AGInventor: BERND BRINKMANN
-
Publication number: 20090136572Abstract: Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof. The present invention relates to an emulsified composition for diluting a cancer antigen peptide or a dimer thereof, comprising a particular ester, a particular surfactant, a particular emulsifier, and a water phase. The present invention also relates to a cancer vaccine composition or specific CTL inducer obtained by freshly diluting and mixing a water phase comprising a cancer antigen peptide or a dimer thereof with the emulsified composition for dilution.Type: ApplicationFiled: January 19, 2006Publication date: May 28, 2009Applicants: DAINIPPON SUMITOMO PHARMA CO., LTD., NOF CORPORATIONInventors: Koichi Saito, Yusuke Okawa
-
Publication number: 20090124709Abstract: The invention concerns methods of validating the purity of n-Dodecyl beta-D-maltoside (DDM), a membrane permeation enhancer used in nasal and oral drug delivery methods, using HPLC and Mass Spectrometry techniques.Type: ApplicationFiled: September 9, 2008Publication date: May 14, 2009Inventors: Douglas L. Cole, Jing J. Zhang
-
Patent number: 7511014Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: June 15, 2006Date of Patent: March 31, 2009Assignee: Novartis AGInventors: Thomas Cavanak, Ulrich Posanski
-
Publication number: 20090053268Abstract: The present invention provides compositions and products, such as waxes and lubricants, comprising a plurality of nanoparticles dispersed in a continuous phase comprising a vegetable oil derived material, such as one or more vegetable oils or a synthetic product derived from one or more vegetable oils. Incorporation of nanoparticles in the present compositions is beneficial for providing mechanical, thermal and/or chemical properties useful for a selected product or product application. In some compositions of the present invention, for example, incorporation of the nanoparticle component provides compositions derived from one or more vegetable oils exhibiting enhanced mechanical stability, hardness, viscosity, thermal stability and mechanical strength.Type: ApplicationFiled: August 22, 2007Publication date: February 26, 2009Inventors: Juan J. DePablo, Mary Jo Biddy
-
Patent number: 7494680Abstract: Provided is a fat or oil composition containing the following components (A), (B) and (C): (A) 100 parts by weight of a fat or oil containing from 0.1 to 10 wt. % of a monoglycerol monofatty acid ester, from 1 to 64.9 wt. % of a monoglycerol trifatty acid ester, and from 35 to 98.9 wt. % of a monoglycerol difatty acid ester having an unsaturated fatty acid content, in fatty acid components, of from 80 to 100 wt. %; (B) from 0.1 to 3.0 parts by weight of a diglycerol fatty acid ester containing from 40 to 100% of a difatty acid ester having an unsaturated fatty acid content, in the fatty acid components, of from 70 to 100 wt. %; and (C) from 0.01 to 2 parts by weight of an antioxidant.Type: GrantFiled: June 1, 2004Date of Patent: February 24, 2009Assignee: Kao CorporationInventors: Junya Moriwaki, Masao Shimizu, Tsutomu Nishide, Shin Koike
-
Publication number: 20090022790Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.Type: ApplicationFiled: September 23, 2008Publication date: January 22, 2009Inventors: Robert P. Flath, John K. Masselink
-
Publication number: 20090005463Abstract: Solubilizers are described which comprise a) one or more ethoxylated fatty alcohols according to formula (I) in which R1 is a linear or branched alkyl radical having 6 to 12 carbon atoms and n is on average a number from 2 to 12, b) one or more ethoxylated triglycerides whose acyl radicals are derived from linear or branched saturated fatty acids having 6 to 22 carbon atoms, and c) water and which are liquid and clear at room temperature and do not comprise addition products of ethylene oxide and simultaneously propylene oxide onto fatty alcohols. The solubilizers are suitable in particular for producing cosmetic, dermatological or pharmaceutical formulations.Type: ApplicationFiled: June 27, 2008Publication date: January 1, 2009Inventors: Wiebke Johannpeter, Wibke Stelter
-
Patent number: 7452864Abstract: Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: GrantFiled: January 28, 2004Date of Patent: November 18, 2008Assignee: Lipopeptide ABInventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Publication number: 20080248998Abstract: Composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 ?m.Type: ApplicationFiled: June 16, 2008Publication date: October 9, 2008Applicant: AVENTIS PHARMA SAInventors: Isabelle CHACORNAC, Patricia PROBECK
-
Publication number: 20080249192Abstract: A wax mixture containing esters of at least one of pentaerythritol, dipentaerythritol, an tripentaerythritol and partial glycerides and a self-emulsifying base containing the wax mixture and an emulsifier which can be a nonionic emulsifier, anionic emulsifier and mixtures of the emulsifiers with an HLB value of at least 10.Type: ApplicationFiled: March 26, 2005Publication date: October 9, 2008Inventors: Caroline Goget, Ulrich Issberner, Rolf Kawa, Catherine Weichold
-
Publication number: 20080193540Abstract: The invention relates to the field of solid medicaments that are intended for the oral administration of active ingredients. The aim of the invention is to prevent the improper use of solid, oral medicaments for any user other than the therapeutic use(s) officially approved by the appropriate public health authorities. More specifically, the invention relates to a solid, oral drug form which is characturised in that it comprises: A) at least one caking agent; and B) at least one viscosifying agent, such as to prevent the misuse thereof.Type: ApplicationFiled: November 21, 2005Publication date: August 14, 2008Applicant: Flamel TechnologiesInventors: Gerard Soula, Frederic Dargelas
-
Publication number: 20080166413Abstract: In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point of not higher than 35° C., such that when the formulation is placed in continuous contact with the skin of a mammalian patient, it is softened to a consistency to effect substantial application of the unit dose of said therapeutic agent onto a desired skin area of the mammalian patient within a time period of less than 10 minutes.Type: ApplicationFiled: March 19, 2008Publication date: July 10, 2008Applicant: PharmaKodex LimitedInventors: John Nicholas Staniforth, Michael John Tobyn
-
Publication number: 20080161276Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.Type: ApplicationFiled: August 4, 2005Publication date: July 3, 2008Inventors: Markus Johnsson, Fredrik Joabsson, Fredrik Tiberg
-
Publication number: 20080159984Abstract: This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.Type: ApplicationFiled: April 14, 2005Publication date: July 3, 2008Inventor: Shmuel A. Ben-Sasson
-
Publication number: 20080139392Abstract: The present invention relates to biocompatible microemulsion systems designed for controlled release drug delivery applications formulated with phospholipids such as lecithin (surfactant), a lipophilic additive (linker) containing 9 or more carbons in their alkyl group and hydrophilic-lipophilic balance (HLB) of 5 or less, and a surfactant-like hydrophilic additive (linker) containing between 6 to 9 carbon atoms in their alkyl tail. The combination of linkers and phospholipids produce formulations capable of delivering high concentrations of poorly soluble drugs into epithelial tissue using low surfactant concentrations, with minimum cytotoxic side effects.Type: ApplicationFiled: December 12, 2006Publication date: June 12, 2008Inventors: Edgar Joel Acosta-Zara, Shuhong Yuan
-
Patent number: 7381422Abstract: The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based medicaments. A suitable method of production disclosed herein additionally comprises cold filtering a mixture of a polynucleotide, block copolymer and cationic surfactant, thereby sterilizing the formulation. The method of the present invention also eliminates the need for thermal cycling of the formulation, thereby reducing the time and expense required to produce large quantities of a formulation during commercial manufacturing. The present invention also relates to novel cationic lipids.Type: GrantFiled: December 2, 2003Date of Patent: June 3, 2008Assignee: Vical IncorporatedInventors: Joel Enas, Andrew Geall
-
Patent number: 7332528Abstract: There are provided safe, tasteless, odorless, non-aqueous liquid spray compositions formulated for administration to the nasal cavity consisting essentially of pharmacologically acceptable non aqueous liquid carrier in which said bioactive material is directly insoluble, a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier, a pharmacologically acceptable water soluble glycol soluble in said ester and a pharmacologically acceptable water soluble bio-active material soluble in said glycol but not directly soluble in the carrier. There are also provided methods of producing and administering such compositions.Type: GrantFiled: September 10, 2003Date of Patent: February 19, 2008Inventor: Leonard Mackles
-
Publication number: 20080026014Abstract: A stick for the topical or transmucosal application of a skin care or active agent onto and via the nasal mucosa, respectively, is provided, wherein the stick material contains a composition of at least one carrier substance and at least one skin care or active agent, which is capable of acting on the nasal mucosa and/or being resorbed by it or which contains at least one volatile substance that acts on the deeper respiratory tract and/or is being resorbed by the deeper respiratory tract. Furthermore, the use of a medical skin care or cosmetical stick or of a stick material or of a refill cartridge containing said material for the topical or transmucosal application is described.Type: ApplicationFiled: October 31, 2003Publication date: January 31, 2008Inventor: Olaf Michel
-
Patent number: 7314638Abstract: The present invention relates to a simple and effective method for preparing a tamsulosin HCl sustained-release tablet and a tamsulosin HCl sustained-release tablet produced thereby. The method comprises the steps of: dissolving tamsulosin HCl as an active ingredient in an organic solvent; dissolving the tamsulosin HCl solution in hydroxypropylmethylcellulose phthalate to prepare a binder solution; and kneading the binder solution with a hydroxypropylmethylcellulose phthalate/glyceryl dibehenate mixture as an excipient and allows tamsulosin HCl to be released at uniformly controlled amounts in a subtained-release manner in vivo by controlling drug release rate according to different pH environments in vivo, so that it shows improved bioavailability and minimized side effects.Type: GrantFiled: June 15, 2004Date of Patent: January 1, 2008Assignee: Kyungdong Pharm. Co., Ltd.Inventors: Byoung-Suk Lee, Ah-Ram Lee, Jong-Sik Park, Eun-Ju Kim, Hyung-Joon Gil
-
Patent number: 7285283Abstract: A paper substrate impregnated with an emulsion containing: (a) a polyol poly-12-hydroxystearate; (b) an oil component selected from the group consisting of a dialkyl ether, a dialkyl carbonate, a glyceride, a hydrocarbon, a silicone oil, and mixtures thereof; (c) up to about 20% by weight of a humectant; (d) up to about 10% by weight of an irritation-soothing agent; (e) up to about 10% by weight of a consistency factor; (f) up to about 15% by weight of a co-emulsifier; and (g) from about 5 to 25% by weight of water, all weights being based on the weight of the emulsion.Type: GrantFiled: January 10, 2002Date of Patent: October 23, 2007Assignee: Cognis Deutschland GmbH & Co. KGInventors: Guido Baumoeller, Rolf Kawa, Stephan Eichhorn
-
Patent number: 7261907Abstract: A non-stoichiometric clathrate of lipid and sulfur has been shown to effectively stabilize nerve cell membranes. As such, said compound has proven useful in a variety of neuropsychiatric disorders such as, addiction, depression, autism, Tourette's syndrome, and the like.Type: GrantFiled: August 30, 2005Date of Patent: August 28, 2007Inventor: Morris Mann
-
Patent number: 7189413Abstract: Degradable blend of polycaprolactone and crystallization modifier especially suitable for use in the controlled release of biologically active proteinsType: GrantFiled: February 14, 2002Date of Patent: March 13, 2007Assignee: Genzyme CorporationInventors: Pericles Calias, Robert J. Miller, James R. Olson
-
Patent number: 7122553Abstract: The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped irinotecan in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds and cardiolipin. The liposomes of the present invention can be either multilamellar vesicles and unilamellar vesicles, as desired.Type: GrantFiled: November 19, 2003Date of Patent: October 17, 2006Assignee: NeoPharm, Inc.Inventors: Aquilur Rahman, Imran Ahmad
-
Patent number: 7115667Abstract: An ophthalmic fluid containing at least one triglyceride, diglyceride, or monoglyceride which is chemically similar or compatible with compounds found naturally in the lipid layer of the tear film of an ocular substrate. Preferably the glycerides are derived from a fatty acid containing at least one unsaturated bond in a cis-configuration in the fatty acid residue. The ophthalmic fluid is arranged in use to provide a protective film across a tear film of an ocular substrate. Furthermore, the ophthalmic fluid is also arranged in use to provide a protective film intermediate a lipid layer of the tear film of the ocular substrate and a contact lens.Type: GrantFiled: February 18, 2004Date of Patent: October 3, 2006Assignee: Planned Products Pty Ltd.Inventor: Anthony William Sly
-
Patent number: 7001621Abstract: Blends comprising a glyceride and ursolic acid and oleanolic acid in weight ratios of 1:99 to 99:1 that contain less than 20 wt % of natural apolar components and/or low molecular weight components, normally present in natural extract for ursolic acid and oleanolic acid do not display the negative off taste of the natural extracts anymore.Type: GrantFiled: May 24, 2001Date of Patent: February 21, 2006Assignee: Loders Croklaan B.V..Inventors: Christiaan Beindorff, Frederick William Cain, John Hugh Pierce, Ulrike Schmid, Erik Schweitzer, Jeroen Nicolaas M. van Straalen
-
Patent number: 6932976Abstract: The present inventions relate to novel skin protectant creams and the use of such creams to cleanse, treat, and protect skin. The skin protectant creams can be topically applied to protect skin from irritants, to block the action of irritants such as enzymes, and to treat skin that has been subject to irritants. The creams can be applied manually or incorporated into disposable applicators, such as wipers or swabs. The skin protectant creams of the present invention are particularly useful in the prevention of severe skin breakdown which can lead to partial thickness skin wounds.Type: GrantFiled: August 8, 2002Date of Patent: August 23, 2005Assignee: Kimberly-Clark Worldwide, Inc.Inventor: JoAnn Brooks
-
Patent number: 6861068Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: January 26, 2004Date of Patent: March 1, 2005Assignee: A.P. Pharma, Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller
-
Patent number: 6818224Abstract: A method is described for preparing a fluid pharmaceutical composition which allows the controlled release of at least one active substance. The method involves mixing a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to 72% by weight of pharmaceutically acceptable solvent, and from 4 to 52% by weight of fatty acid. The composition has a property of gelling instantaneously in the presence of an aqueous phase.Type: GrantFiled: September 17, 2002Date of Patent: November 16, 2004Assignee: UCB, S.A.Inventors: Domenico Fanara, Henri Vranckx, Michel Deleers, Pierre Grognet
-
Patent number: 6790458Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: April 7, 2003Date of Patent: September 14, 2004Assignee: AP Pharma Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller
-
Patent number: 6761903Abstract: The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.Type: GrantFiled: June 8, 2001Date of Patent: July 13, 2004Assignee: Lipocine, Inc.Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad
-
Patent number: 6753011Abstract: Delivery devices capable of delivering one or more active substances by diffusion through plural micropores in the membrane (4) or by osmotic pumping through one or more preformed passageways (5) in the membrane are provided. The device (1) has an about centrally located expandable core (2) completely surrounded by an active substance-containing layer (3), which is completely surrounded by the membrane. The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.Type: GrantFiled: January 15, 2002Date of Patent: June 22, 2004Assignee: Osmotica CorpInventor: Joaquina Faour
-
Patent number: 6730329Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.Type: GrantFiled: February 26, 2002Date of Patent: May 4, 2004Inventor: Jeffrey B. Smith
-
Patent number: 6706281Abstract: A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.Type: GrantFiled: January 2, 2002Date of Patent: March 16, 2004Assignee: Euro-Celtique, S.A.Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang
-
Patent number: 6706263Abstract: Microencapsulated and/or enteric coated compositions containing a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules and a bacterial source which metabolizes urea and ammonia are provided. Also provided are methods of using these compositions to alleviate symptoms of uremia in patients.Type: GrantFiled: April 20, 2000Date of Patent: March 16, 2004Assignee: Kibow Biotech Inc.Inventors: Natarajan Ranganathan, Jack Dickstein
-
Publication number: 20040048934Abstract: Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and an solubilizer. Alternatively, the formulation includes an aqueous solution of solubilizer.Type: ApplicationFiled: April 29, 2003Publication date: March 11, 2004Applicant: G.D. Searle & Co.Inventors: Rajeev Gokhale, Martin J. Griffin, James E. Truelove, James C. Stolzenbach, Aziz Karim, Ajit K. Roy
-
Patent number: 6692767Abstract: Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100° C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.Type: GrantFiled: September 18, 1998Date of Patent: February 17, 2004Assignee: Shire Laboratories Inc.Inventors: Beth A. Burnside, Charlotte M. McGuinness, Edward M. Rudnic, Richard A. Couch, Xiaodi Guo, Alexander K. Tustian
-
Patent number: 6692775Abstract: A gel formulation is combined with a bactericidal concentrate which is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 mho with about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The bactericidal liquid concentrate in the amount of 3.5 to 12 ml in one liter of gel formulation is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.Type: GrantFiled: June 24, 2002Date of Patent: February 17, 2004Assignee: Aqua Med, Inc.Inventor: John D. Young
-
Publication number: 20040029977Abstract: A process for making an emulsion having a particle size of from about 0.1 to 5 &mgr;m involving: (a) providing an oil component having a polarity of up to 5 Debye; (b) providing an emulsifier; (c) providing water; and (d) homogenizing (a)-(c), under pressure, to form the emulsion.Type: ApplicationFiled: May 29, 2003Publication date: February 12, 2004Inventors: Rolf Kawa, Achim Ansmann, Rainer Eskuchen
-
Patent number: 6677327Abstract: The present invention relates to an edible phytosterol or phytostanol composition useful in the food industry and to methods of preparing such an edible composition. The edible composition comprises a phytosterol or phytostanol, an isolated water soluble protein, and optionally an emulsifier, wherein the weight ratio of the protein to the phytosterol or phytostanol is from about 0.2:1 to about 10:1, and the weight ratio of the emulsifier to the phytosterol or phytostanol is from about 0.2:1 to about 5:1. The invention also relates to edible products containing such a composition and to methods for the production of the edible products.Type: GrantFiled: November 24, 1999Date of Patent: January 13, 2004Assignee: Archer-Daniels-Midland CompanyInventor: Thomas V. Gottemoller
-
Patent number: 6673360Abstract: A preferred emulsifier blend includes ethoxylated alcohols containing hydrocarbons of C10-C16 and preferably having on average at least 2.8 ethoxy and/or alcohol groups per chain and a glycerol mono- and/or dioleates, preferably in a ratio of from 9:1 to 4:6. These emulsion blends are particularly useful when mixed with hydroisomerized oils and water, for subsequent application as a spray oil to agricultural crops. The emulsion blends of the present invention also find particular utility when mixed with conventional spray oils and hard water.Type: GrantFiled: January 29, 2003Date of Patent: January 6, 2004Assignees: Platte Chemical Company, Petro CanadaInventor: Michael Fefer
-
Publication number: 20030236310Abstract: The present invention is directed to microdispersions and pharmaceutical compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry, and a synthetic, bioabsorbable, biocompatible polymeric wax comprising the reaction product of a polybasic acid or derivative thereof, a fatty acid and a polyol, the polymeric wax having a melting point less than about 70° C., as determined by differential scanning calorimetry.Type: ApplicationFiled: June 25, 2002Publication date: December 25, 2003Inventors: Aruna Nathan, Joel Rosenblatt, Steven C. Arnold
-
Patent number: 6667059Abstract: A coating for masking or reducing the detectable presence of certain characteristic odor or odors, taste or tastes of pharmaceutical preparations, particularly Valerian extracts, is described. The coating comprises from one to three coating compartments, in any combination or as a single-layer amalgam. The first coating compartment comprises a hydroxyalkyl cellulose and an anti-tackiness agent. The second coating compartment may comprise a sugar and at least one anti-tackiness agent. The third coating compartment may comprise a methacrylate copolymer, a hydroxyalkyl cellulose and an anti-tackiness agent.Type: GrantFiled: May 30, 2001Date of Patent: December 23, 2003Assignee: Ancile Pharmaceuticals, Inc.Inventors: I-Lan T. Sue, Pou-Hsiung Wang, Lori McDonald Smith
-
Patent number: 6667043Abstract: A process for making technical di/triglyceride mixtures involving: (a) providing a vegetable oil; and (b) partially transesterifying the vegetable oil by reacting it with a component selected from the group consisting of a mixture of glycerol and a fatty acid corresponding to formula I: R1COOH (I) wherein R1CO is an acyl group having from 6 to 10 carbon atoms, a mixture of glycerol and a methyl ester of the fatty acid of formula I, and a triglyceride based on the fatty acid of formula I.Type: GrantFiled: August 10, 1998Date of Patent: December 23, 2003Assignee: Cognis Deutschland GmbH & Co. KGInventors: Stefan Podubrin, Achim Ansmann, Rolf Kawa, Richard Ridinger
-
Patent number: 6660775Abstract: The ability of biting midges to locate a target by olfactory emissions of the target is inhibited by dispensing into a spatial area an inhibiting effective amount of at least one inhibiting compound selected from the group consisting of 3-methyl-1-alkene-3-ols of the formula: and 3-methyl-1-alkyn-3-ols of the formula: wherein R1 and R2 are each independently a saturated or unsaturated aliphatic hydrocarbon group containing from 1 to about 12 carbon atoms.Type: GrantFiled: February 19, 2002Date of Patent: December 9, 2003Assignees: BioSensory, Inc., Bedoukian Research, Inc., The United States of America as represented by the Secretary of AgricultureInventors: James A. Nolen, Robert H. Bedoukian, Robert E. Maloney, Daniel L. Kline
-
Patent number: 6652880Abstract: This invention is directed to pharmaceutical compositions for oral administration, wherein the drug or active ingredient is known to have stability problems associated with the use of free fatty acids. The compositions of the invention enhance the solubility of such compounds and improve the storage stability thereof and can be advantageously used in soft-gel and hard-shell capsular formulations. The liquid pharmaceutical compositions, according to the present invention, have a drug dissolved in a liquid vehicle. The liquid vehicle comprising a glyceride of a long chain fatty acid and a lypophilic surfactant having an HLB of less than ten. The composition, according to the invention, is also substantially free of free fatty acids.Type: GrantFiled: December 21, 2001Date of Patent: November 25, 2003Assignee: R.P. Scherer Technologies, Inc.Inventors: Elizabeth Anne Aylwin, Susan Banbury, Josephine Joan Christine Ferdinando, Henrik de Nijs
-
Patent number: 6613355Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: May 11, 2001Date of Patent: September 2, 2003Assignee: A.P. Pharma, Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller
-
Publication number: 20030162748Abstract: The present invention is directed to a lipid-based delivery system for administration of an active drug substance selected from lysolipid derivatives which are particularly useful in the treatment or detection of parasitic infections, especially parasitic infections which cause an elevated PLA2 level in the infected mammal. Preferred parasitic infections are infections wherein the life cycle of the parasite involves the liver and/or spleen of the infected organism.Type: ApplicationFiled: January 21, 2003Publication date: August 28, 2003Inventors: Kent Jorgensen, Jesper Davidsen, Charlotte Vermehren, Sven Frokjer, Ole G Mouritsen